Office of Research Innovation & Technology Transfer
Supporting advances in technology across Versiti.
Office of Research Innovation & Technology Transfer (RITT)
The Office of Research Innovation & Technology Transfer (RITT) at Versiti Blood Research Institute protects technological advances and medical resources across Versiti, transforming them into discoveries that save and improve patient lives. We accomplish this research translation and product development efforts into new medical diagnostic tools for patients; new medical tools for physicians; new tools used for ongoing basic discovery efforts; and new and improved delivery of therapeutics and knowledge for physicians, scientists and people worldwide.
Services
Tech transfer staff provide patent management, licensing and contract negotiation services to scientists and Versiti partners.
Available Technologies
Versiti has a number of patented technologies currently available for licensing. We also have collections of antibodies, transgenic mice and other scientific materials available to the research community.
Education
Versiti, in collaboration with regional tech transfer offices and other organizations in southeastern Wisconsin, has developed a series of web-based video learning modules designed to introduce researchers to the technology transfer process.
A safety improvement to existing Chimeric Antigen Receptor (CAR) therapy that controls cytokine release syndrome. Short peptides are cloned into existing CAR constructs.
Genetically engineered T cells from a patient's own tumor combined with chimeric antigen receptor and vaccine technology offers a lasting cure for solid tumors.
Improved DNA-based diagnostic assay to identify platelet-specific alloantigens involved in immune thrombocytopenias or platelet mismatch of mom and fetus during pregnancy.
Improved and simplified diagnostic assay for von Willebrand Disease (VWD) screening. No need for ristocetin, aggregometer, or platelet reagents, reducing assay costs and false positives, while improving reproducibility.
Lipid-Lowering tPA-K2 to Reduce Atherogenic Lipoproteins to Lower Residual Cardiovascular Risk
The novel link between the intracellular function of tissue-type plasminogen activator (tPA) and Apolipoprotein B (apoB) in hepatocytes shows great promise for developing a drug to lower all bad atherogenic lipoproteins by tPA fragments and reduce cardiovascular risk.
Versiti and its affiliates hold numerous accreditations and licenses, listed here for each Versiti affiliate.
Scientific Programs
Scientific research and training are important parts of Versiti’s mission. Our research programs involve basic and clinical scientists at Versiti Blood Research Institute.
Shared Core Facilities
Versiti Blood Research Institute’s Shared Resources department includes core laboratories, shared equipment and specialized research services.
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking ACCEPT, you consent to the use of all the cookies.